论文部分内容阅读
目的观察普拉克索联合卡左双多巴缓释片(息宁)治疗中晚期帕金森病(PD)患者的临床疗效。方法将中晚期PD患者54例随机分为治疗组和对照组,每组27例,治疗组给予普拉克索联合息宁治疗,对照组给予息宁治疗。比较2组治疗前后帕金森综合评分量表(UPDRS)评分和不良反应。结果治疗前2组UPDRSⅡ评分和UPDRSⅢ评分比较差异均无统计学意义(P>0.05),治疗后2组UPDRSⅡ评分和UPDRSⅢ评分均下降(P<0.05),且治疗组低于对照组(P<0.05)。治疗组不良反应发生率为77.78%高于对照组的22.22%,差异有统计学意义(χ2=15.962,P<0.05)。结论普拉克索联合息宁治疗中晚期PD可显著改善帕金森病患者的运动障碍,提高其生存质量。但普拉克索不良反应不应忽视。
Objective To observe the clinical efficacy of pramipexole combined with card Zuobium Dopa sustained-release tablets (Ning) in the treatment of patients with Parkinson’s disease (PD). Methods 54 cases of advanced PD patients were randomly divided into treatment group and control group, with 27 cases in each group. The treatment group received pramipexole plus quinine and the control group received ningning treatment. The two groups were compared before and after treatment Parkinson’s comprehensive rating scale (UPDRS) score and adverse reactions. Results There were no significant differences in UPDRS Ⅱ and UPDRS Ⅲ scores between the two groups before treatment (P> 0.05). The UPDRS Ⅱ and UPDRS Ⅲ scores of both groups decreased after treatment (P <0.05), and were lower in the treatment group than in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was 77.78% higher than that in the control group (22.22%), the difference was statistically significant (χ2 = 15.962, P <0.05). Conclusion Pramipexole combined with ningling in the treatment of advanced stage PD can significantly improve the dyskinesia of Parkinson’s disease patients and improve its quality of life. However, pramipexole adverse reactions should not be ignored.